LPX-TI641

DRUG3 trials

Sponsors

LAPIX Therapeutics Inc.

Conditions

Atopic Dermatitis (AD)Autoimmune DiseasesMultiple SclerosisPsoriasis (PsO)Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)

Phase 1

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

CompletedNCT05853835

LAPIX Therapeutics Inc.Autoimmune Diseases, Multiple Sclerosis

Start: 2023-10-30End: 2024-11-01Updated: 2025-01-23

Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis

RecruitingNCT06628206

LAPIX Therapeutics Inc.Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA)

Start: 2024-12-15End: 2026-01-15Target: 48Updated: 2025-11-20

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

RecruitingNCT06982352

LAPIX Therapeutics Inc.Atopic Dermatitis (AD), Psoriasis (PsO)

Start: 2025-06-15End: 2026-04-15Target: 48Updated: 2025-12-19